Nephronophthisis 3 (NPHP3) Cell Models for Research

Nephronophthisis 3 (NPHP3) is a rare autosomal recessive ciliopathy characterized by cystic kidney disease, leading to end-stage renal disease (ESRD) typically in childhood or adolescence. The exact incidence is unknown but estimated at 1 in 50,000 to 1 in 100,000 live births. NPHP3 mutations account for approximately 1-3% of all nephronophthisis cases. The disease is progressive, with most patients requiring renal replacement therapy by the second decade of life. Extrarenal manifestations include retinal degeneration, liver fibrosis, and cerebellar vermis hypoplasia (Joubert syndrome). The clinical impact is severe, with significant morbidity and mortality, and no curative treatment exists, only supportive care.

NPHP3 provides an excellent model for studying ciliary function, renal development, and cystic kidney disease mechanisms. The NPHP3 protein is involved in ciliary transport and cell polarity. Research on NPHP3 has broader implications for other ciliopathies and polycystic kidney disease (PKD). The availability of patient-derived cell lines and animal models facilitates mechanistic studies. Open questions include the precise role of NPHP3 in ciliary signaling and the development of targeted therapies. Gene-edited cell models are essential for functional validation of NPHP3 mutations and for drug screening.

Although NPHP3 is not a cancer gene, its dysfunction leads to cystic kidney disease through dysregulation of several pathways:

• • Ciliary signaling: NPHP3 is part of the NPHP-Joubert-MKS module, localizing to cilia and regulating ciliary transport. Loss of NPHP3 disrupts ciliary function, leading to aberrant signaling.
• • Wnt signaling: NPHP3 interacts with inversin (INVS) and nephrocystin-1 (NPHP1) to modulate non-canonical Wnt signaling, affecting planar cell polarity (PCP) and tubulogenesis.
• • Hippo signaling: NPHP3 may influence Hippo pathway, affecting cell proliferation and apoptosis.
• • mTOR signaling: Dysregulation of mTOR has been implicated in cystogenesis, and NPHP3 may interact with this pathway.

Data from ClinVar and literature.

• • Ciliary signaling: NPHP3 is essential for ciliary gate integrity and protein trafficking. Loss leads to accumulation of signaling molecules (e.g., Shh, Wnt) in cilia.
• • Wnt/PCP pathway: NPHP3 interacts with inversin to regulate cytoplasmic vs. nuclear β-catenin. Dysregulation causes abnormal convergent extension and tubular dilation.
• • mTOR pathway: Cystic kidneys often show hyperactivation of mTOR. NPHP3 loss may contribute to this.
• • Apoptosis and proliferation: Altered signaling leads to increased apoptosis and proliferation, contributing to cyst formation.

Organoids derived from patient iPSCs recapitulate cystic phenotypes and are valuable for drug testing.

• • Pcy mouse: Naturally occurring NPHP3 mutation (pcy) causes progressive polycystic kidney disease, resembling NPHP3.
• • NPHP3 knockout mouse: Targeted deletion of Nphp3 leads to renal cysts, retinal degeneration, and situs inversus.
• • Zebrafish models: Morpholino or CRISPR-mediated knockdown of nphp3 causes renal cysts and ciliary defects.
• • Rat models: Nphp3 mutant rats (e.g., Wistar polycystic kidney rat) are used for therapeutic studies.

CRISPR-Cas9 technology enables the generation of isogenic cell lines with precise NPHP3 mutations. These include:

• • NPHP3 knockout cell lines: Complete loss of function to study null phenotypes.
• • NPHP3 point mutation knock-in lines: Introduction of patient-specific missense mutations (e.g., p.Arg415Trp) to study hypomorphic effects.
• • NPHP3 reporter lines: Tagging with GFP or luciferase to track protein expression and localization.
• • NPHP3 overexpression lines: Stable expression of wild-type or mutant NPHP3 for rescue experiments.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, isogenic backgrounds. These models are essential for functional validation and drug screening.

Gene-edited NPHP3 cell lines are used to validate disease-causing variants. For example, introducing a patient-specific mutation into a wild-type cell line and observing ciliary defects confirms pathogenicity. Knockout lines are used to study downstream effects on ciliary signaling and gene expression. CRISPR screens can identify genetic modifiers of NPHP3 loss.

Isogenic pairs (wild-type vs. NPHP3 knockout) are ideal for high-throughput screening of compounds that rescue ciliary defects or reduce cyst formation. These models allow identification of drugs that specifically target the mutant phenotype. Resistance mechanisms can be studied by exposing cells to drugs and selecting for resistant clones.

CRISPR synthetic lethality screens in NPHP3-deficient cells can identify vulnerabilities that may serve as therapeutic targets. For example, genes that are essential only in NPHP3 knockout cells could be targeted to kill cystic cells. Additionally, gene-edited cells can be used to identify biomarkers of disease progression.